Gold prices steady ahead of Fed decision, Trump’s tariff deadline
Investing.com - BioLife Solutions (NASDAQ: BLFS) reported first quarter EPS of $-0.04, $0.04 better than the analyst estimate of $-0.08. Revenue for the quarter came in at $22.7M versus the consensus estimate of $22.03M.
Guidance
BioLife Solutions sees FY 2025 revenue of $95.50M-$99.00M versus the analyst consensus of $95.45M.
BioLife Solutions’s stock price closed at $24.00. It is down -4.69% in the last 3 months and up 32.23% in the last 12 months.
BioLife Solutions saw 1 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See BioLife Solutions’s stock price’s past reactions to earnings here.
According to InvestingPro, BioLife Solutions’s Financial Health score is "good performance".
Check out BioLife Solutions’s recent earnings performance, and BioLife Solutions’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar